ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Volatility and Risk
ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
Valuation and Earnings
This table compares ProQR Therapeutics and Artiva Biotherapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProQR Therapeutics | $18.36 million | 11.02 | -$47.73 million | ($0.50) | -3.84 |
| Artiva Biotherapeutics | N/A | N/A | -$83.86 million | ($3.30) | -3.47 |
ProQR Therapeutics has higher revenue and earnings than Artiva Biotherapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares ProQR Therapeutics and Artiva Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProQR Therapeutics | -331.33% | -84.87% | -37.78% |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
Analyst Ratings
This is a breakdown of recent recommendations for ProQR Therapeutics and Artiva Biotherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProQR Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
ProQR Therapeutics currently has a consensus target price of $7.33, indicating a potential upside of 281.94%. Artiva Biotherapeutics has a consensus target price of $39.00, indicating a potential upside of 240.61%. Given ProQR Therapeutics’ higher possible upside, equities analysts plainly believe ProQR Therapeutics is more favorable than Artiva Biotherapeutics.
Summary
ProQR Therapeutics beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
